Proniras

Proniras

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Proniras Corporation Secures New Series B Financing and Names New Board Members to Support Phase 1 Study of Novel Treatment for Opiate Withdrawal

Details:

The net proceeds will be used to support a Phase 1 clinical study of the Company’s lead program PRN-001-01 (tezampanel), a novel modulator of glutaminergic signaling designed to treat patients seeking to recover from opioid addiction and associated conditions.

Lead Product(s): Tezampanel

Therapeutic Area: Psychiatry/Psychology Product Name: PRN-001-01

Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Accelerator Life Science Partners

Deal Size: $9.0 million Upfront Cash: Undisclosed

Deal Type: Series B Financing February 01, 2024

ASK
US

Upload
your Marketing & Sales content

Proniras

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Proniras Corporation Announces National Institute on Drug Abuse (NIDA) Grant Award to Pursue Treatment for Opioid Withdrawal

Details:

The grant supports development of the company’s proprietary molecule, tezampanel, as a treatment for opioid withdrawal syndrome. Tezampanel has demonstrated positive results in a variety of preclinical models of seizure disorder in clinical studies.

Lead Product(s): Tezampanel

Therapeutic Area: Psychiatry/Psychology Product Name: LY-293,558

Highest Development Status: UndisclosedProduct Type: Small molecule

Partner/Sponsor/Collaborator: National Institute on Drug Abuse

Deal Size: $12.3 million Upfront Cash: Undisclosed

Deal Type: Funding September 17, 2020

ASK
US

Upload
your Marketing & Sales content